Skip to main content
TipRanks
Go Ultimate75% OFF

FINDEX Inc. (3649) AI Stock Analysis

0 Followers
JP:3649

FINDEX Inc.

(TSE/TYO:3649)

Select Model
Rating:75Outperform
Price Target:JPY 934.00â–²(16.75% Upside)
Action:reiterated
Date:11/08/26

The company's exceptional financial strength, characterized by a debt-free balance sheet, high profitability, and strong cash flows, is the primary driver of the score. This is partially offset by a weak technical outlook, with the stock trading below key moving averages and exhibiting negative momentum. The moderate valuation and attractive 3.25% dividend yield provide a balanced support to the overall assessment.

Positive Factors
High and improving profitabilityStrong profitability provides FINDEX with substantial earnings capacity relative to revenue and indicates that recent growth is translating into attractive returns. Margins have expanded materially from earlier years, supporting reinvestment, resilience, and durable operating leverage over the next several quarters.
Negative Factors
Uneven revenue growthAlthough 2025 revenue growth was positive, the history of declines and near-flat performance shows that expansion has not been consistently sustained. Uneven demand can make future revenue planning less predictable and may limit the pace at which strong margins translate into durable earnings growth.

FINDEX Inc. (3649) vs. iShares MSCI Japan ETF (EWJ)

-30%-20%-10%0%10%20%30%JP:3649-11.67%EWJ+6.46%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
JPY 19.44B
Dividend Yield
3.34%
Average Volume (3M)
57.59K
Price to Earnings (P/E)
18.8
Beta (1Y)
0.46
Revenue Growth
2.22%
EPS Growth
-8.47%
Country
Japan
Employees
325
Sector
Healthcare
Sector Strength
51
Industry
Medical - Healthcare Information Services

FINDEX Inc. Business Overview & Revenue Model

Company Description

FINDEX Inc., a company established in Tokyo in 1985, focuses on the creation, production, and distribution of medical technology systems across Japan. Their portfolio features Claio, a comprehensive medical imaging database management system utilized...

FINDEX Inc. Financial Statement Overview

Summary

Financial health is excellent. The balance sheet is pristine with zero debt and a strong equity base, driving an ROE above 20%. Profitability is high with a 65.2% gross margin and 20.6% net margin, supported by robust cash flow generation where operating cash flow covers net income by 1.3x. The only minor watch item is a deceleration in revenue growth to 6.0%.

Income Statement

90Very Positive

Balance Sheet

95Very Positive

Cash Flow

90Very Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue6.13B6.11B5.84B5.19B4.54B4.97B
Gross Profit4.02B3.98B3.55B3.33B2.72B2.56B
EBITDA2.02B2.09B1.83B1.78B1.32B1.25B
Net Income1.13B1.26B1.16B1.06B722.78M636.03M
Balance Sheet
Total Assets6.92B6.81B6.69B5.94B4.98B4.56B
Cash, Cash Equivalents and Short-Term Investments2.47B1.68B1.73B2.69B2.41B2.17B
Total Debt0000020.00M
Total Liabilities1.24B1.34B1.08B1.09B939.06M1.04B
Stockholders Equity5.65B5.44B5.60B4.84B4.04B3.51B
Cash Flow
Free Cash Flow01.62B1.87B559.87M621.08M681.02M
Operating Cash Flow01.65B1.90B842.84M693.85M750.35M
Investing Cash Flow0-297.86M-2.43B-296.94M-230.16M-490.37M
Financing Cash Flow0-1.41B-412.54M-270.49M-142.02M-186.34M

FINDEX Inc. Technical Analysis

Technical Analysis SentimentNegative
Last Price800.00

Price Trends

50DMA859.22Negative
100DMA852.26Negative
200DMA835.00Negative

Market Momentum

MACD-13.39Positive
RSI38.09Neutral
STOCH29.73Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:3649, the sentiment is Negative. The current price of 800.00 is below the 20-day moving average (MA) of 843.85, below the 50-day MA of 859.22, and below the 200-day MA of 835.00, indicating a bearish trend. The MACD of -13.39 indicates Positive momentum. The RSI at 38.09 is Neutral, neither overbought nor oversold. The STOCH value of 29.73 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:3649.

FINDEX Inc. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

JP:3649 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
JP:3939JP:393982OutperformJPY 23.85B16.25―1.89%12.07%30.31%
JP:3649JP:364975OutperformJPY 20.72B18.75―3.34%2.22%-8.47%
JP:2413JP:241372OutperformJPY 1.18T25.0811.33%1.26%9.48%2.08%
JP:4483JP:448372OutperformJPY 232.67B31.20―0.51%20.50%19.27%
JP:4480JP:448054NeutralJPY 56.52B32.9911.30%―21.01%10.15%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%

* Healthcare Sector Average

Performance Comparison

-40%-20%0%JP:3649JP:2413JP:4480JP:3939JP:4483Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
JP:3649 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
JP:3649FINDEX Inc.800.00-84.41-9.54%
JP:2413M3 1681.00-918.33-35.33%
JP:4480Medley, Inc.1780.00-870.00-32.83%
JP:3939Kanamic Network Co., LTD.489.00-28.32-5.47%
JP:4483JMDC Inc.3440.00-759.57-18.09%

FINDEX Inc. Corporate Events

FINDEX Issues H1 FY2026 Results Presentation With Strong Legal Disclaimers

Aug 13, 2026

FINDEX Inc. has released its H1 FY2026 financial results presentation with extensive disclaimers that the information is provided solely for informational purposes. The company stresses that the materials, including business plans and target figures,...

FINDEX Posts Softer H1 Profits but Lifts Dividend and Confirms 2026 Outlook

Aug 13, 2026

FINDEX Inc. reported modest revenue growth for the first half of 2026, with net sales edging up 0.6% year-on-year to ¥3.15 billion, while operating profit fell 7.0% and profit attributable to owners of parent dropped 18.2%, pressuring earnings per sh...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 07, 2026